CureVac Stock: Recovery Continues Despite Weekly Fluctuations

CureVac shares showed mixed performance in recent trading, hovering around the €2.80 mark with slight losses predominating. The stock slipped 1.1 percent to €2.78 on Friday morning, continuing Thursday's downward trend. Despite these short-term fluctuations, the Tübingen-based biotech firm has demonstrated remarkable resilience, recovering more than 35 percent from its 52-week low of €2.06 reached in late April 2024. However, the current price still sits approximately 78 percent below January 2025's 52-week high of €4.98. Analysts maintain optimism about CureVac's prospects, setting an average price target of $3.90 with expectations of €0.793 earnings per share for the full 2024 fiscal year. Investors are now looking ahead to the fourth quarter earnings report scheduled for April 23, 2025.

Impressive Financial Turnaround

The company's latest quarterly results reveal a dramatic financial transformation. For the quarter ending September 30, 2024, CureVac reported earnings of $1.66 per share, a substantial improvement from the $0.24 per share loss recorded in the same period last year. Revenue performance was even more striking, with the company generating $542.57 million—more than 30 times the previous year's figure of approximately $18 million. This remarkable growth reflects CureVac's strategic pivot toward intensified research activities, suggesting the biotech firm's restructuring efforts are yielding positive results.

Ad

Fresh CureVac information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Source StockWorld